Targeted probiotic therapy in irritable bowel syndrome: a clinical evaluation on Clostridium butyricum CBM588 and Bifidobacterium longum W11
Alexander Bertuccioli(University of Urbino), Annalisa Belli(University of Urbino), Giordano Bruno Zonzini(University of Urbino), Nadia Lazzerini(CTO Hospital), Mirko Ragazzini, Davide Sisti(University of Urbino), Chiara Maria Palazzi(Ospedale Santa Chiara)
Cited by 3
Related Papers
Possible Therapeutic Effects of Adjuvant Quercetin Supplementation Against Early-Stage COVID-19 Infection: A Prospective, Randomized, Controlled, and Open-Label Study
|International Journal of General Medicine|2021|183
Potential Clinical Benefits of Quercetin in the Early Stage of COVID-19: Results of a Second, Pilot, Randomized, Controlled and Open-Label Clinical Trial
|International Journal of General Medicine|2021|177
Quercetin as a possible complementary agent for early-stage COVID-19: Concluding results of a randomized clinical trial
|Frontiers in Pharmacology|2023|54
The Role of Short-Chain Fatty Acids, Particularly Butyrate, in Oncological Immunotherapy with Checkpoint Inhibitors: The Effectiveness of Complementary Treatment with Clostridium butyricum 588
|Microorganisms|2024|15
The Potential Role of Probiotics, Especially Butyrate Producers, in the Management of Gastrointestinal Mucositis Induced by Oncologic Chemo-Radiotherapy
|International Journal of Molecular Sciences|2024|13